Skip to content

Flurbiprofen

    DEA Class; Rx

    Common Brand Names; Ansaid, Flurprofen, Froben, Froben SR

    NSAIDs

    Propionic acid NSAID; longer half-life allows for twice daily dosing; oral formulation used for RA, OA, dysmenorrhea; ophthalmic form used for inhibition of intraoperative miosis. Oral administration causes an increased risk of serious gastrointestinal adverse effects and may cause an increased risk of serious cardiovascular events; use lowest effective dose for the shortest possible duration.

    For the treatment of mild pain and moderate pain.

    For the treatment of osteoarthritis or rheumatoid arthritis.

    For intraoperative miosis inhibition.

    For the treatment of ankylosing spondylitis

    For the acute treatment of migraine

    Absolute: hypersensitivity to flurbiprofen, ASA allergy, history of aspirin triad, CABG

    Relative: Bleeding disorders, duodenal/gastric/peptic ulcer, stomatitis, ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)

    Edema

    Fluid retention

    UTI

    Abdominal pain with cramps

    Diarrhea

    Headache

    Hypersecretory conditions

    Nausea

    Amnesia

    Bloody stools/vomit

    Blurred vision

    Depression

    Diplopia

    Gastritis

    Gastrointestinal hemorrhage

    Mental/mood changes

    Rhinitis

    Skin rash

    Tinnitus

    Anorexia

    Anxiety

    Constipation

    Dizziness

    Drowsiness

    Flatulence

    Flushing

    Insomnia

    Irritability

    Nervousness

    Tachycardia

    Use caution in asthma (bronchial), cardiac disease, CHF, hepatic/renal impairment, HTN, SLE

    Potential risk of adverse cardiovascular events

    Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include the elderly, or those with impaired renal function, hypovolemia, heart failure, liver dysfunction, salt depletion, and individuals taking diuretics, ACE inhibitors, or ARBs

    Heart Failure (HF) risk

    Pregnancy Category: C; avoid in late pregnancy

    Lactation: excreted in breast milk; not recommended

    Adults

    300 mg/day PO; not to exceed 100 mg/dose PO.

    Elderly

    300 mg/day PO; not to exceed 100 mg/dose PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Tablet

    • 50mg
    • 100mg

    DEA Class; Rx


    Common Brand Names; Cataflam, Voltaren-XR, Dyloject, Cambia, Zipsor, Zorvolex

    Diclofenac topical (Rx, OTC)

    Brand and Other Names: Flector Transdermal Patch, Voltaren Gel, Pennsaid topical solution, Solaraze Gel, Licart, Voltaren Arthritis Pain

    NSAIDs

    NSAID available in intravenous, oral, topical, and ophthalmic formulations

    Analgesic and antipyretic properties

    Increases risk of serious GI events and may increase risk of serious CV events; use lowest dose for shortest time

    Rheumatoid Arthritis,  Osteoarthritis, Ankylosing Spondylitis, Dysmenorrhea 

    Acute Pain

    Indicated for treatment of mild to moderate acute pain in adults

    Acute Migraine

    Indicated for acute treatment of migraine attacks with or without aura, Not for prophylaxis. Use lowest effective dose for shortest duration consistent with individual patient treatment goals

    Hypersensitivity (eg, anaphylaxis, serious skin reactions) to diclofenac or any components of the product

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs

    In the setting of coronary artery bypass graft (CABG) surgery

    Zipsor capsules are contraindicated in patients with history of hypersensitivity to bovine protein

    >10%

    Zorvolex

    Edema (33%)

    Nausea (27%)

    Headache (13%)

    Zipsor

    Nausea (16.5%)

    Headache (12.5%)

    1-10%

    Cambia

    Nausea (3%)

    Dizziness (1%)

    Diclofenac potassium tablets

    Abdominal pain

    Constipation

    Diarrhea

    Dyspepsia

    Flatulence

    Gross bleeding/perforation

    Heartburn

    Nausea

    GI ulcers (gastric/duodenal)

    Vomiting

    Abnormal renal function

    Anemia

    Dizziness

    Ophthalmic Solution (Voltaren Ophthalmic)

    Mild ocular stinging, irritation

    May slow corneal wound healing

    Lacrimation

    Increased IOP

    Keratitis

    Dizziness

    Insomnia

    Pain

    Fever

    Chills

    Use caution in patients with bronchospasm, cardiac disease, CHF, hepatic porphyria, hypertension, fluid retention, severe renal impairment, smoking, systemic lupus erythematosus

    Platelet aggregation and adhesion may be decreased; may prolong bleeding time

    Use caution in blood dyscrasias or bone marrow depression; also with thrombocytopenia, agranulocytosis, and aplastic anemia

    Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals, those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers

    Increase risk of hyperkalemia may occur, especially in renal disease, diabetics, the elderly, and concomitant use of agents that may induce hyperkalemia; monitor potassium closely

    Pregnancy; There are no adequate and well-controlled studies in pregnant women; data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive

    Lactation; The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition

    Adults

    Rheumatoid Arthritis

    Diclofenac potassium: 50 mg PO q8-12hr

    Diclofenac sodium: 50 mg PO q8hr or 75 mg PO q12hr

    Extended release: 100 mg PO once daily; may be increased to 100 mg PO q12hr

    Osteoarthritis

    Diclofenac potassium: 50 mg PO q8-12hr

    Diclofenac sodium: 50 mg PO q8hr or 75 mg PO q12hr

    Extended release: 100 mg PO once daily; may be increased to 100 mg PO q12hr

    Zorvolex: 35 mg PO TID

    Ankylosing Spondylitis

    Diclofenac sodium: 25 mg PO 4 or 5 times daily

    Diclofenac potassium: 50 mg PO q12hr

    Dysmenorrhea

    Immediate-release: 100 mg PO once, then 50 mg PO q8hr PRN

    Acute Pain

    Indicated for treatment of mild to moderate acute pain in adults

    Immediate-release tablets: 100 mg PO once, then 50 mg PO q8hr PRN

    Extended-release tablets

    Zipsor: 25 mg PO QID PRN

    Zorvolex: 18 mg or 35 mg PO TID

    Use the lowest effective dose for the shortest duration consistent with individual patient treatment goal

    Acute Migraine

    Indicated for acute treatment of migraine attacks with or without aura

    Cambia: 50 mg (1 packet) in 30-60 mL of water, mixed well and drunk immediately

    Not for prophylaxis

    Use lowest effective dose for shortest duration consistent with individual patient treatment goals

    Pediatric 

    Acute Pain

    Zipsor only

    Indicated for relief of mild-to-moderate pain in adult and pediatric patients aged ≥12 years

    <12 years: Safety and efficacy not established

    ≥12 years: 25 mg PO QID PRN

    Diclofenac potassium

    Packet

    50mg/single-dose packet (generic, Cambia)

    Delivers 50-mg dose when mixed in water

    Tablet

    50mg (generic)

    capsule

    25mg (Zipsor)

    Diclofenac sodium

    Tablet, delayed release

    25mg (generic)

    50mg (generic)

    75mg (generic)

    Tablet, extended-release

    100mg (generic)

    capsule

    18mg (Zorvolex)

    35mg (Zorvolex)

    Ophthalmic solution

    • 0.1%

    DEA Class; Rx


    Common Brand Names; Cataflam, Voltaren-XR, Dyloject, Cambia, Zipsor, Zorvolex

    Diclofenac topical (Rx, OTC)

    Brand and Other Names: Flector Transdermal Patch, Voltaren Gel, Pennsaid topical solution, Solaraze Gel, Licart, Voltaren Arthritis Pain

    NSAIDs

    NSAID available in intravenous, oral, topical, and ophthalmic formulations

    Analgesic and antipyretic properties

    Increases risk of serious GI events and may increase risk of serious CV events; use lowest dose for shortest time

    Rheumatoid Arthritis,  Osteoarthritis, Ankylosing Spondylitis, Dysmenorrhea 

    Acute Pain

    Indicated for treatment of mild to moderate acute pain in adults

    Acute Migraine

    Indicated for acute treatment of migraine attacks with or without aura, Not for prophylaxis. Use lowest effective dose for shortest duration consistent with individual patient treatment goals

    Hypersensitivity (eg, anaphylaxis, serious skin reactions) to diclofenac or any components of the product

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs

    In the setting of coronary artery bypass graft (CABG) surgery

    Zipsor capsules are contraindicated in patients with history of hypersensitivity to bovine protein

    >10%

    Zorvolex

    Edema (33%)

    Nausea (27%)

    Headache (13%)

    Zipsor

    Nausea (16.5%)

    Headache (12.5%)

    1-10%

    Cambia

    Nausea (3%)

    Dizziness (1%)

    Diclofenac potassium tablets

    Abdominal pain

    Constipation

    Diarrhea

    Dyspepsia

    Flatulence

    Gross bleeding/perforation

    Heartburn

    Nausea

    GI ulcers (gastric/duodenal)

    Vomiting

    Abnormal renal function

    Anemia

    Dizziness

    Ophthalmic Solution (Voltaren Ophthalmic)

    Mild ocular stinging, irritation

    May slow corneal wound healing

    Lacrimation

    Increased IOP

    Keratitis

    Dizziness

    Insomnia

    Pain

    Fever

    Chills

    Use caution in patients with bronchospasm, cardiac disease, CHF, hepatic porphyria, hypertension, fluid retention, severe renal impairment, smoking, systemic lupus erythematosus

    Platelet aggregation and adhesion may be decreased; may prolong bleeding time

    Use caution in blood dyscrasias or bone marrow depression; also with thrombocytopenia, agranulocytosis, and aplastic anemia

    Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals, those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers

    Increase risk of hyperkalemia may occur, especially in renal disease, diabetics, the elderly, and concomitant use of agents that may induce hyperkalemia; monitor potassium closely

    Pregnancy; There are no adequate and well-controlled studies in pregnant women; data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive

    Lactation; The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition

    Adults

    Rheumatoid Arthritis

    Diclofenac potassium: 50 mg PO q8-12hr

    Diclofenac sodium: 50 mg PO q8hr or 75 mg PO q12hr

    Extended release: 100 mg PO once daily; may be increased to 100 mg PO q12hr

    Osteoarthritis

    Diclofenac potassium: 50 mg PO q8-12hr

    Diclofenac sodium: 50 mg PO q8hr or 75 mg PO q12hr

    Extended release: 100 mg PO once daily; may be increased to 100 mg PO q12hr

    Zorvolex: 35 mg PO TID

    Ankylosing Spondylitis

    Diclofenac sodium: 25 mg PO 4 or 5 times daily

    Diclofenac potassium: 50 mg PO q12hr

    Dysmenorrhea

    Immediate-release: 100 mg PO once, then 50 mg PO q8hr PRN

    Acute Pain

    Indicated for treatment of mild to moderate acute pain in adults

    Immediate-release tablets: 100 mg PO once, then 50 mg PO q8hr PRN

    Extended-release tablets

    Zipsor: 25 mg PO QID PRN

    Zorvolex: 18 mg or 35 mg PO TID

    Use the lowest effective dose for the shortest duration consistent with individual patient treatment goal

    Acute Migraine

    Indicated for acute treatment of migraine attacks with or without aura

    Cambia: 50 mg (1 packet) in 30-60 mL of water, mixed well and drunk immediately

    Not for prophylaxis

    Use lowest effective dose for shortest duration consistent with individual patient treatment goals

    Pediatric 

    Acute Pain

    Zipsor only

    Indicated for relief of mild-to-moderate pain in adult and pediatric patients aged ≥12 years

    <12 years: Safety and efficacy not established

    ≥12 years: 25 mg PO QID PRN

    Diclofenac potassium

    Packet

    50mg/single-dose packet (generic, Cambia)

    Delivers 50-mg dose when mixed in water

    Tablet

    50mg (generic)

    capsule

    25mg (Zipsor)

    Diclofenac sodium

    Tablet, delayed release

    25mg (generic)

    50mg (generic)

    75mg (generic)

    Tablet, extended-release

    100mg (generic)

    capsule

    18mg (Zorvolex)

    35mg (Zorvolex)

    Ophthalmic solution

    • 0.1%